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Intravenous tissue plasminogen activator (TPA) improves patient chances to recover from stroke by inducing 
mostly partial recanalization of large intracranial thrombi. TPA activity can be enhanced with ultrasound including 
2 MHz transcranial Doppler (TCD). TCD identifies residual blood flow signals around thrombi, and, by delivering 
mechanical pressure waves, exposes more thrombus surface to circulating TPA. The international multi-center 
CLOTBUST trial showed that ultrasound enhances thrombolytic activity of a drug in humans thereby confirming multi- 
disciplinary experimental research conducted worldwide for the past 30 years.
In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 
2 hours after TPA bolus occurred in 25% of patients treated with TPA+TCD compared to 8% who received TPA 
alone (p=0.02). Complete clearance of a thrombus and dramatic recovery of brain functions during treatment are 
feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain 
perfusion seen in the Target CLOTBUST group resulted in a trend of 13% more patients achieving favorable 
outcome at 3 months, subject for a pivotal trial. However, different results were achieved in a small TRUMBI trial 
and another study that used Transcranial Color-Coded Duplex Sonography (TCCD). Adverse bio-effects of mid- 
KHz (300) ultrasound promote bleeding, including brain areas not-affected by ischemia while exposure to multi- 
frequency / multi-element duplex ultrasound resulted in a trend towards higher risk of hemorrhagic transformations.
To further enhance the ability of TPA to break up thrombi, current ongoing clinical trials include phase II studies 
of a single beam 2 MHz TCD with perflutren-lipid microspheres. Enhancement of intra-arterial TPA delivery is being 
clinically tested with 1.7-2.1 MHz pulsed wave ultrasound (EKOS catheter). Multi-national dose escalation studies 
of microspheres and the development of an operator independent ultrasound device are underway.
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INTRODUCTION
Unlike thrombolysis for myocardial ischemia, the pilot 
clinical studies of thrombolysis for ischemic stroke did 
not document dramatic, “Lazarus” or “on the table” 
clinical recovery during treatment.
1-3 Subsequent pivotal 
trials of TPA have not reported any differences between 
the groups at 2 and 24 hours post treatment in the 
pre-specified end-points.
4-7 However, a post-hoc analysis 
of the NINDS trial
8 showed that by 24 hours, 27% of 
TPA-treated patients improved by ≥10 points on the 
National Institutes of Health Stroke Scale (NIHSS) or 
resolved their neurological deficit completely compared Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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to 12% in the placebo group (p=0.002). Therefore, some 
patients may have experienced early clinical recovery 
presumably due to fast thrombus dissolution, but the 
overall number of these events was low.
Early clinical improvement after stroke usually occurs 
after arterial recanalization.
9-12 A recent meta-analysis 
confirmed the recanalzation hypothesis by showing that 
the occurrence of recanalization is associated with a 4- 
to 5-fold increase in the odds of good final functional 
outcome and a 4- to 5-fold reduction in the odds of 
death.
13 These results lend strong support to the use of 
restoration of vessel patency as a surrogate end point in 
phase II trials of pharmacological recanalization agents 
and in trials comparing novel to existing predicate 
recanalization devices in acute ischemic stroke. Since 
early recanalization can lead to dramatic recovery,
9-12 
any additional enhancement of TPA-associated thrombus 
dissolution can possibly produce even higher early 
recovery rates among patients with ischemic stroke. 
The ability of an ultrasonic mechanical pressure wave 
to enhance thrombolysis has been documented in 1970’s, 
14,15 and confirmed by many in experimental models.
16-20 
The likely mechanism that emerged from these in vitro 
and  in vivo experiments is the ability of ultrasound to 
agitate flow around and through the thrombus thus 
delivering more TPA to target binding sites. In stroke 
patients, ultrasound can promote TPA delivery to the 
areas with stagnant flow near occlusion.
Although low kilohertz frequencies better potentiate 
TPA effects,
21 these systems are not available for 
clinical practice due to safety concerns and inability to 
image vasculature with this frequency/wavelength range. 
Meanwhile, 1-2.2 MHz frequencies can also enhance 
TPA-induced thrombus dissolution utilizing different 
mechanisms such as fluid streaming around clot surface, 
dis-aggregation of fibrin fibers, and creating more 
binding sites for TPA without heating or cavitation.
22,23 
This frequency range is safely used for diagnostic 
ultrasound examinations. 
Portable diagnostic 2 MHz TCD equipment can be 
used the emergency room to continuously monitor TPA 
infusion is acute ischemic stroke patients.
24 With prior 
training and experience in interpretation of TCD, this 
test, particularly in combination with urgent carotid/ 
vertebral duplex scanning, can yield high degrees of 
accuracy for detection and localization of arterial 
occlusion as well as assessment of recanalization at 
bedside.
24,25 In addition, TCD can be complementary to 
other imaging modalities such as CTA by showing 
real-time flow findings (real-time embolization, colla-
teralization of flow with extracranial internal carotid 
artery disease, alternating flow signals indicative of steal 
phenomenon).
26 Finally, real time flow findings during 
TCD-monitoring has been shown to be associated with 
long-term functional outcome.
27,28
Once abnormal residual flow signals are identified, an 
ultrasound beam can be steadily focused at presumed 
intra-cranial thrombus location, and arterial recanali-
zation can be monitored in real time.
24 When intrave-
nous TPA infusion was continuously monitored with 
2 MHz TCD,
24 we have observed early recanalization 
and dramatic recovery rates higher than expected.
1 This 
non-randomized study of patients treated with TPA
24 
suggested potential therapeutic effect of TCD and led to 
a prospective randomized clinical trial. 
The CLOTBUST Trial
The CLOTBUST (Combined Lysis of Thrombus in 
Brain ischemia using transcranial Ultrasound and 
Systemic TPA, Fig. 1) was a phase II clinical rando-
mized multi-center international trial with centers in 
Houston, Barcelona, Edmonton, Calgary.
29 It had 
pre-specified safety and signal of efficacy end-points and 
a pre-determined sample size of 63 patients per group.
29 
All enrolled patients had an acute ischemic stroke, and 
were treated with a standard 0.9 mg/kg dose of intra-
venous TPA therapy within 3 hours of symptom onset. 
All patients also had MCA occlusions on pre-treatment 
TCD. They were randomized (1:1) to continuous TCD 
monitoring (Target) or placebo monitoring (Control). 
Safety end-point was symptomatic brain hemorrhage 
(sICH) causing worsening of the neurological deficit by 
4 or more NIH Stroke Scale (NIHSS) points. Primary 
combined activity end-point was complete recanalization 
on TCD or dramatic clinical recovery by the total 
NIHSS score ≤ 3 points, or improvement by ≥ 10 Tsivgoulis G and Alexandrov AV. Ultrasound Enhanced Thrombolysis for Stroke
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Figure 1. Reported controlled clinical trials of ultrasound-enhanced systemic thrombolysis for acute ischemic 
stroke.
27,28,34 The Figure was reproduced with permission from Andrei Alexandrov (n; total number of patients 
enrolled in both control and target groups, Transducer; images of actual sources of ultrasound and their size relative 
to patient head, Tissues exposed; images of beam paths as ultrasound propagates through the brain, sICH; percent 
rates of symptomatic intracranial hemorrhages, CR; complete recanalization at the end of monitoring period, mRS 
0-1; modified Rankin scores at 3 months follow-up (? -percent or actual number not reported in the original 
publication
34).
NIHSS points within 2 hours after TPA bolus. Clinical 
investigators were blinded to group assignment (active 
or sham monitoring) done by sonographers.
All projected 126 patients received TPA and were 
randomized 1:1 to target (median pre-treatment NIHSS 
16 points) or control (NIHSS 17 points). Age, occlusion 
location on TCD and time to TPA bolus were similar 
between groups. sICH occurred in 4.8% Target and 
4.8% Controls. Primary end-point was achieved by 
31 (49%, Target) vs 19 (30%, Control), p=0.03. At 
3 months, 42% Target and 29% Control patients 
achieved favorable outcomes (mRS 0-1 points), NS. This 
trend indicates feasibility of a pivotal phase III clinical 
trial that, at 274 patients per group, would be properly 




Transcranial duplex technology was recently tested in 
a smaller randomized clinical trial.
30 Duplex transducers 
are different from the ones used in CLOTBUST since 
they generate multiple small beams at dual emitting 
frequencies, one for Doppler and one for gray scale 
imaging (Fig. 1). One of major limitations of this 
technology that there are no reliable head frames for 
transducer fixation, and most studies are to be carried 
out hand-held. In addition, the mechanical index of these 
scanners is higher than TCD and no dose escalation 
study was performed to determine how little ultrasound 
is needs to enhance thrombolysis without safety con-
cerns that would be outlined below.
Eggers et al. evaluated 25 patients (11 Target 
TPA+duplex monitoring, 14 Controls TPA alone) and 
reported a trend in the Target group towards higher Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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Table 1. Reported controlled clinical trials of microsphere-potentiated ultrasound-enhanced systemic thrombolysis for acute 
ischemic stroke using Trancranial Doppler (TCD) and Transcranial Color-Coded (TCCD) Ultrasonography
Trial F ECA Design R REC** AsxICH** sICH** Outcome at 3 months
TCD
Molina et al.
40 2 MHz galactose-based US/MS/tPA (n=38)
vs. US/tPA (n=37) 
vs. tPA (n=36)   
N 71% 23% 3% 56%
(mRS 0-2)
Alexandrov et al.
41 2 MHz perfultren-lipid US/MS/tPA (n=12)
vs. US/tPA (n=3)




43 2 MHz* galactose-based US/MS/tPA (n=9)
vs. TPA (n=11)
Y 48% 78% 0% NA
Perren et al.





N 64% NA 9% NA
US; Continuous Ultrasound Monitoring, MS; microspheres, tPA; tissue plasminogen activator, R; Randomization, REC; 
recanalization at the end of TCD monitoring, sICH; symptomatic intracranial hemorrhage, AsxICH; asymptomatic intracranial 
hemorrhage, mRS; modified Rankin Scale, NA; not available. *patients received monitoring with a pulsed wave 2 MHz phased 
array Doppler and intermittent exposure to dual frequency duplex, **in the active treatment group (microsphere-potentiated 
ultrasound-enhanced systemic) thrombolysis,***at three months
recanalization rates, more hemorrhagic transformations 
(18% sICH rate), and better outcomes at 3 months 
compared to patients who received TPA alone.
30 This 
study did not have a pre-determined sample size, and the 
results may be affected by a small number of patients 
enrolled. More studies are needed to evaluate the 
potential of transcranial duplex technology to enhance 
thrombolysis.
The same group and others
31-33 reported provocative 
findings that patients who are not eligible for systemic 
TPA therapy may potentially benefit from continuous 
monitoring with ultrasound alone since, hypothetically, 
ultrasound may help facilitate the endogenous throm-
bolytic process that leads to spontaneous recanalizations 
in acute stroke patients. It is unclear if only partial 
recanalization can be induced by ultrasound alone, and 
if this exposure would result in a significant difference 
at 3 months justifying a large clinical trial. In any 
case, there is no clear data regarding the benefit of 
ultrasound monitoring without TPA and TPA treatment 
should not be substituted with ultrasound alone in 
patients otherwise eligible for thrombolytic therapy 
within 3 hours of symptom onset.
Furthermore, different experimental strategies are 
being tested in an extended time window for acute 
stroke treatment, and continuous exposure to ultrasound 
may find its application while patient may be receiving 
other agents such as GP IIb-IIIa antagonists or direct 
thrombin inhibitors or awaits intra-arterial procedures.
Ultrasound transducers were also incorporated into a 
catheter for intra-arterial delivery of a thrombolytic drug 
(EKOS Corporation). This intra-arterial device uses 1.7 
- 2.1 MHz pulsed wave ultrasound with the emitting 
power of 400 mW, parameters similar to extracranially 
applied transcranial Doppler. The EKOS catheter is now 
being tested in phase II-III Interventional Management of 
Stroke (IMS) trials.
34
Therapeutic, i.e. non-imaging ultrasound
35 has been 
tested in the TRanscranial low-frequency Ultrasound- 
Mediated thrombolysis in Brain Ischemia (TRUMBI) 
trial.
36 First, the investigators used a very low KHz 
system (<40 KHz) that produced intolerable tinnitus and 
was withdrawn from clinical testing (Daffertshofer M, 
unpublished data). It was replaced by a mid KHz system 
operating at 300 KHz (Fig. 1). The trial was terminated 
after 26 patients were enrolled with a 36% rate of Tsivgoulis G and Alexandrov AV. Ultrasound Enhanced Thrombolysis for Stroke
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Figure 2. PMD flow tracks showing individual and 
multiple perflutren-lipid microsphere permeation to areas 
with no detectable residual flow pre-treatment (white 
circles) and residual blood flow improvement following 
the administration of microspheres. The Figure was re-
produced with permission from Andrei Alexandrov.
symptomatic hemorrhage in the Target group and no 
signal of efficacy on early recanalization or clinical 
outcomes at 3 months.
36 The trial demonstrated adverse 
bio-effects of mid-KHz ultrasound that promote bleed-
ing, including brain areas not-affected by ischemia.
36 
Further research should determine if “standing” pressure 
waves and endothelial disruption may cause these ad-
verse effects. If confirmed in vivo models, this will have 




Experimental data have suggested that ultrasound- 
enhanced thrombolysis can be further amplified by 
adding gaseous microspheres,
37-39 safe ultrasound 
contrast agents, are micron-sized lipid shells that when 
exposed to ultrasound, expand and produce stable 
cavitation with stronger reflected echoes. This is used to 
generate ultrasound images with better resolution. At the 
same time, microspheres agitate fluid where they are 
released by ultrasound and this is useful in drug delivery 
and mechanical “grinding” of a thrombus. In fact, micro-
spheres have their own ability to lyse thrombi without 
a lytic drug.
37
Several studies have been reported with different types 
of commercially available microspheres
40-43 (Table). 
Molina et al pioneered this approach in stroke patients 
and reported the largest study to date that compared 
the CLOTBUST Target arm to the CLOTBUST Target 
insonation protocol combined with Levovist air micro-
spheres (Schering AG).
40  Investigators demonstrated that 
at 2 hours after TPA bolus the TPA+TCD+Levovist 
group achieved a 55% sustained recanalization rate 
compared to 38% in the TPA+TCD group of the 
CLOTBUST trial. The safety and feasibility of infusion 
of a new and more stable C3F8 perfultren-lipid micro-
spheres in patients treated with ultrasound-enhanced 
thrombolysis has recently been reported in a small phase 
IIA randomized clinical trial.
41 Interestingly, in 75% of 
patients, μS permeated to areas with no pre-treatment 
residual flow, and in 83%, residual flow velocity 
improved at median of 30 min from start of μS infusion 
(range 30 s-120 min) by median of 17 cm/s, or 118% 
above pre-treatment values (Fig. 2). 
Larrue et al recently randomized patients with acute 
(<3 hours) middle cerebral artery main stem occlusion as 
demonstrated by CT or MR angiography to either trans-
cranial duplex ultrasound continuous monitoring combined 
with intravenous galactose-based microspheres and rt-PA 
(combined treatment group), or rt-PA alone (control 
group).
43 Their trial was prematurely discontinued on the 
basis of safety reasons since a high rate of asymptomatic 
intracerebral hemorrhage was demonstrated on gradient- 
echo MRI in the combined treatment group (78%). 
However, none of the intracerebral hemorrhages was 
symptomatic and the fact that asymptomatic hemorrhagic 
transformation in the setting of acute cerebral ischemia 
has not been associated with poor outcome both in the 
NINDS
44  and the ECASS trial
45 should be taken into 
account when interpreting the results of the former Journal of Clinical Neurology: Vol. 3, No. 1, 2007
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study. It is further unclear why data safety monitoring 
board was not appointed for this study and why a dose 
de-escalation decision was not made (i.e. reduce time of 
exposure to ultrasound or reduce the dose of micro-
spheres). In its current design, the study does not allow 
to decide whether excessive hemorrhagic transformation 
rate was attributed to duplex ultrasound or microspheres 
since controls received just TPA and no ultrasound.
Finally, Perren et al studied the safety and feasibility 
of TCCD ultrasound monitoring combined with a second 
generation, phospholipid encapsulated sulphur hexafluo-
ride microsphere (SonoVue) and intravenous systemic 
thrombolysis in patients with acute middle cerebral artery 
occlusion. Patients who received Microsphere-potentiated 
Ultrasound-enhanced Thrombolysis seemed to fare better 
in terms of improvement in NIHSS-score and sustained 
a more marked improvement in their residual blood flow 




Currently, an international multi-center controlled 
TUCSON trial of a new and more stable perfultren-lipid 
microspheres (MRX 801, www.imarx.com) is underway.
46 
A total of 72 patients with acute intracranial arterial 
occlusion as demonstrasted by CT or MR angiography 
will be randomized to Microspheres-potentiated Ultra-
sound-enhanced Thrombolysis (4 groups with increasing 
doses of perfultren-lipid microspheres) versus TPA treat-
ment alone.
Microspheres offer a mechanical way to amplify 
stroke therapies, and can be developed as a new kind of 
drugs or devices to augment brain perfusion, drug and 
nutrient delivery within the existing and at an extended 
time window. One problem on the way to develop 
ultrasound and microsphere assisted stroke therapies is 
the need of an experienced sonographer to find intra-
cranial thrombus, and expose its surface to residual flow 
in order to lodge more TPA and agitate stagnant flow. 
Personnel with these skills are lacking in most emergency 
centers. Future studies will focus on the development of 
an operator-independent ultrasound device that can be 
used by existing medical personnel regardless of their 
experience in diagnostic ultrasound.
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